Shire Buys Fosrenol Patent Rights for Up to $31 M
Shire will pay AnorMED $18 million when Fosrenol is approved in the U.S. and $7 million when it's approved in European Union, the company said.
The agreement also gives Shire a 12-month option to purchase the Japanese patents for $6 million when the drug is approved in Japan.
Shire will no longer have royalty obligations to AnorMED...
To view the full article, register now.